CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

British Journal of Cancer

Volumn 109, Issue 11, 2013, Pages 2803-2809

  Yamamoto, N ^a   Murakami, H ^a   Hayashi, H ^b   Fujisaka, Y ^b   Hirashima, T ^c   Takeda, K ^d   Satouchi, M ^e   Miyoshi, K ^f   Akinaga, S ^f   Takahashi, T ^a   Nakagawa, K ^b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e HYOGO CANCER CENTER   (Japan)

^f KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

C Met inhibitor; CYP2C19 polymorphism; Erlotinib; Non small cell lung cancer; Phase I study; Tivantinib

Indexed keywords

CYTOCHROME P450 2C19; ERLOTINIB; TIVANTINIB;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; GENOTYPE; HUMAN; JAPANESE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SEPSIS; SINUS BRADYCARDIA; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG DOSAGE CALCULATIONS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINAZOLINES; QUINOLINES;

EID: 84888859773     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.588     Document Type: Article

References (26)

1. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH (1997) Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 74: 301-309. (Pubitemid 27321800)
2. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516. (Pubitemid 351767118)
3. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymalepithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286: 20666-20676.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
5. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS (2012) Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118: 5903-5911.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. (Pubitemid 351521864)
7. Kubota T, Chiba K, Iga T (2001) Frequency distribution of CYP2C19, CYP2D6, and CYP2C9 mutant-alleles in several different populations. Xenobio Metab Dispos 16: 69-74.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
9. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824. (Pubitemid 350002184)
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
12. Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62: 589-596. (Pubitemid 34106436)
13. Qiao H, Hung W, Tremblay E, Wojcik J, Gui J, Ho J, Klassen J, Campling B, Elliott B (2002) Constitutive activation of Met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86: 665-677. (Pubitemid 34839968)
14. Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Von Pawel J, Shuster D, Schwartz B, Sandler A (2013) MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC). ESMO congress: Abstract 3410.
15. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB (2012) Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 13: 391-395.
16. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Pharmacol Ther 72: 702-710. (Pubitemid 36021009)
17. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-3315.
18. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
19. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79: 103-113. (Pubitemid 43069582)
20. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T (2012) Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31: 807-814.
21. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, Kuo C, Wang HJ, Hoon DS (2003) c-Met expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480-1488. (Pubitemid 36418405)
22. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S (2000) u-PA and c-Met mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87: 644-649. (Pubitemid 30620405)
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
24. Trusolino L, Bertotti A, Comoglio PM (2001) A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643-654. (Pubitemid 34014865)
25. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku N (2013) The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 24(6): 1653-1659.
26. Yap TA, de Bono JS (2010) Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 9: 1077-1079.